ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

apraglutide

Also written as “Apraglutide”, “FE203799 GLP-2 analogue” and “FE 203799”.

Its studies are mostly in Short Bowel Syndrome · Graft vs Host Disease · Renal Insufficiency, Chronic · Hodgkin Disease, led by 2 companies.

Drug pageApraglutide: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 22, 202012 company-led studies, 2 open or runningNext primary completion: Oct 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ironwood Pharmaceuticals92 open or runningphase 3since Oct 22, 2020Oct 22, 2020Oct 30, 2027phase 3 · NCT05018286
GlyPharma Therapeuticsits history only30 open or runningphase 2since Nov 13, 2017Nov 13, 2017none ahead

Also a collaborator on its studies: PSI CRO.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ironwood Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2017Named apraglutideINNProposed as its International Nonproprietary Name in WHO's List 118 · before, FE 203799, FE203799
  2. Oct 22, 2020First study: phase 3 study in Short Bowel SyndromeFirst studyNCT04627025 · 164 enrolled · United States, Argentina, Belgium and more
  3. Dec 30, 2020Phase 1 study in Renal Insufficiency, ChronicNCT04699032 · 16 enrolled · United States
  4. May 27, 2021Phase 2 study in Short Bowel SyndromeNCT04964986 · 10 enrolled · Belgium, France
  5. Jul 6, 2021Phase 3 study in Short Bowel SyndromeNCT05018286 · 158 enrolled · United States, Argentina, Belgium and more
  6. Feb 8, 2022Phase 2 study in Graft vs Host DiseaseNCT05415410 · 31 enrolled · United States, Germany, Portugal and more
  7. Jan 20, 2023Phase 1 study in Hepatic ImpairmentNCT05706623 · 16 enrolled · Germany, Slovakia
  8. Feb 22, 2023Phase 1 study in Healthy SubjectsNCT05995704 · 42 enrolled · Netherlands
  9. Jul 11, 2023Phase 1 study in Healthy SubjectsNCT06002555 · 34 enrolled · Netherlands
  10. Jul 12, 2026Phase 3 study in Short Bowel SyndromeNCT07742735 · 124 planned · United States, Argentina, Australia and more

Ahead

  1. Oct 30, 2027Primary completion: phase 3 study in Short Bowel SyndromeNCT05018286
  2. Oct 2028Primary completion: phase 3 study in Short Bowel SyndromeNCT07742735

TargetBeta

GCG →read by rule
“A synthetic, long-acting glucagon-like peptide-2 (GLP-2) agonist, with intestinotrophic activity”NCIt, by rule

Studies

All 9 Ironwood Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07742735Short Bowel Syndrome · United States, Argentina, Australia and more3RecruitingOct 2028124
NCT06002555Healthy Subjects · Netherlands1CompletedSep 22, 202334
NCT05995704Healthy Subjects · Netherlands1CompletedJul 24, 202342
NCT05706623Hepatic Impairment · Germany, Slovakia1CompletedApr 4, 202316
NCT05415410Graft vs Host Disease · United States, Germany, Portugal and more2TerminatedDec 17, 202431
NCT05018286Short Bowel Syndrome · United States, Argentina, Belgium and more3Active, not recruitingOct 30, 2027158
NCT04964986Short Bowel Syndrome · Belgium, France2CompletedJun 6, 202310
NCT04699032Renal Insufficiency, Chronic · United States1CompletedJul 5, 202116
NCT04627025Short Bowel Syndrome · United States, Argentina, Belgium and more3CompletedJan 2, 2024164

How it is read

Names in the registry

  • “Apraglutide”, 8 entries
  • “FE203799 GLP-2 analogue”, 2 entries
  • “apraglutide”, 1 entry
  • “FE 203799”, 1 entry
  • “FE203799”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.